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Control of serum potassium during fasting in patients with end-stage
renal disease. In order to evaluate internal potassium balance in patients
with end-stage renal disease (ESRD), epinephrine (0.015 g/kg/min)
was infused intravenously into normal control (N 9) and ESRD
subjects (N = 7) after a 26 hour fast. Hyperkalemia developed in ESRD
patients after 16 hours of fasting, as compared with control subjects (P
0.02). The hemodynamic response to epinephrine was similar in the
two groups. During epinephrine infusion for one hour, the serum
potassium decreased in normal subjects, from 4.3 0.2 mEq/liter to 3.9
0.1 mEq/liter, but did not change in ESRD patients (P = 0.005).
Serum CO2 declined in ESRD, but not in control subjects, while glucose
levels were not different in the two groups. Plasma aldosterone was
significantly higher in fasting ESRD patients and failed to decrease
during epinephrine infusion as compared to controls. Plasma insulin
levels remained low in both groups even though serum glucose levels
increased. These results demonstrate that hyperkalemia occurs during
fasting in ESRD probably as the result of insulinopenia, and suggest
that a diminished response to epinephrine may contribute to hyperka-
lemia.
Hyperkalemia is usually attributed to excessive potassium
intake or metabolic acidosis, in combination with limited potas-
sium excretion, in patients with end-stage renal disease
(ESRD). It is not well recognized that hyperkalemia also occurs
in fasting patients with ESRD independently of the serum
bicarbonate concentration. The chief cause of fasting hyperka-
lemia may be suppression of plasma insulin levels, but the lack
of a statistical correlation between potassium and insulin levels
[1] suggest that other factors, such as catecholamines, may be
of importance. The present study was designed to evaluate the
role of insulin and catecholamines (epinephrine, in particular) in
the control of serum potassium concentration during fasting in
chronic hemodialysis patients.
Methods
Eight ESRD patients on chronic hemodialysis and nine
normal subjects participated in the study. ESRD patients were
excluded from study if they had diabetes mellitus, angina
pectoris, an unstable cardiac rhythm, congestive cardiomyop-
athy, or if they were receiving digitalis glycosides or an anglo-
tensin converting enzyme inhibitor. Prostaglandin synthetase
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inhibitors and J3-adrenergic blocking agents were discontinued
at least one week prior to study. ESRD patients underwent
routine outpatient hemodialysis one day prior to study and
shortly after completion of the study. Each patient ate breakfast
at 0600 on day one and thereafter refrained from all intake
except water (10 to 15 mI/kg body wt/24 hours). Control
subjects followed a similar protocol except that they had free
access to water and they did not undergo dialysis. All partici-
pants were admitted to the General Clinical Research Center at
the University of Alabama at Birmingham, eight hours after
onset of fasting, and remained at bed rest from 2100 on the day
of admission until the completion of the study. At 0800 on day
two, epinephrine was infused intravenously at a rate of 0.015
tg/kg body wt/min for one hour. This dose of epinephrine is
considerably lower than the amount required to produce plasma
epinephrine levels similar to those seen with stress. After
completion of the epinephrine infusion, the study was termi-
nated and the patients were fed. Cardiac rhythm was monitored
continuously, and heart rate and blood pressure were recorded
every 15 minutes during the period of infusion. Blood was
sampled at eight hour intervals after admission and every 15
minutes during epinephrine infusion (from the opposite antecu-
bital vein) for measurement of serum potassium, CO2 content
and glucose, as well as plasma insulin, aldosterone, renin, and
catecholamines (epinephrine and norepinephrine). Levels of
p-hydroxybutyric acid and lactic acid were measured before
and at 30 and 60 minutes after epinephrine infusion. Thus, the
initial blood sample was obtained after each subject had fasted
for eight hours. The serum potassium level rose more rapidly
than anticipated (peak serum potassium level, 7.7 mEq/liter) in
one ESRD patient; a transient junctional rhythm developed
near the end of epinephrine infusion but rapidly resolved when
the infusion was discontinued and the patient was fed. There-
after, serum potassium was measured at least one hour prior to
epinephrine infusion, in addition to the times previously spec-
ified. Another patient required a continuous infusion of 10%
dextrose in water, between hour 16 of the fast and the comple-
tion of the study, in order to keep his serum potassium below 6
mEq/liter. All blood studies obtained after the onset of dextrose
administration (that is, after 16 hours of fasting) in this patient
were excluded from the data. As in the prior patient, hyperka-
lemia promptly resolved after the patient was fed.
Sodium, potassium, chloride, and bicarbonate levels were
measured on a multiple sequential analyzer. Glucose was
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Table 1. Patient population
Age
years Male
Sex
Female
Weight
kg
TSF
mm
MAMC
cm
Normal
ESRD
P
36 348 4
0.04
1
4
8
5
66.5 6.1
64.8 5.2
NS
10.3 2.4
5.6 0.4
NS
25.4 1.5
25.8 0.8
NS
Abbreviations are: TSF, triceps skinfold thickness; MAMC, mid-arm
muscle circumference.
measured by the glucokinase method. Plasma insulin [2], aldo-
sterone [3], renin activity [4], epinephrine and norepinephrine
[5] concentrations were determined by radioimmunoassay. /3-
hydroxybutyric acid [6] and lactic acid [7] were determined as
previously described. Statistical analysis of the results was
done in part with the CLINFO Computer Facility of the
General Clinical Research Center. The statistical significance of
differences between group means for variables measured prior
to epinephrine infusion was determined by Student's t-test for
unpaired samples. The statistical analyses for the data following
epinephrine infusion were accomplished in two stages. First the
response over time for the individual patients and controls were
summarized in terms of the estimated slopes and intercepts for
linear regressions. The assumption of a straight line appeared to
be adequate to represent the data which were taken at a
maximum of five time points for each person. Then these
estimated coefficients were analyzed by multivariate and uni-
variate analysis of covarience with adjustments being made for
unequal race, sex and age distributions between the control and
patient groups. This method of comparison between the regres-
sion parameter estimates was considered to be better than the
usual analysis of covarience methods because it does not
require an assumption of parallel lines for the persons in a
group, but assumes rather that the parameters are themselves
random variables with non-zero expectations which are char-
acteristic of the two groups [8]. All values are expressed as the
mean SEM, and a P value of 0.05 or less was considered to
represent a significant difference. Written informed consent was
obtained from each participant. The study was approved by the
Scientific Advisory Committee of the General Clinical Research
Center, and by the Institutional Review Board, the University
of Alabama at Birmingham.
Results
The general characteristics of the two groups are shown in
Table 1. The ESRD group was significantly older than the
normal subjects (P = 0.04) but the two groups were similar with
respect to body weight and anthropometric measurements.
Subjects in both groups experienced a similar increase in heart
rate (7 4 beats/mm in ESRD patients and 7 3 beats/mm in
normal subjects) during the epinephrine infusion. Blood pres-
sure was higher in the ESRD patients (151/88 9/5 mm Hg) as
compared to normal subjects (108/63 6/3 mm Hg), but neither
group changed significantly in response to epinephrine.
Biochemical changes prior to epinephrine infusion are de-
picted in Table 2. The serum potassium level was significantly
higher in ESRD patients as compared to normal subjects after
16 hours (P = 0.02) and 26 hours (P = 0.03) of fasting. Urinary
potassium excretion, between hours 10 and 26 of fasting, was
Table 2. Biochemical changes during fasting
Hours of fastinga
8 16 26
Potassium mEqiliter
Normal 4.1 0.1 4.0 0.1 4.3 0.2
ESRD 4.7 0.3 4.8 0.3 5.2 0.3
P NS 0.02 0.03
CO2 content mEq/liier
Normal 23.8 0.5 25.2 0.4 23.7 0.4
ESRD 24.8 1.2 25.3 0.9 23.1 1.0
P NS NS NS
Glucose mg/dl
Normal 87 2 88 2 82 3
ESRD 90±3 88±4 76±6
P NS NS NS
Insulin sUImi
Normal 4.8 0.7 7.9 4.2 6.3 2.5
ESRD 5.6 0.9 4.8 0.8 4.7 LI
P NS NS NS
Free fatty acids p.Eq/liter
Normal 794 222 571 136 698 151
ESRD 690 201 492 106 469 95
P NS NS NS
Renin activity ng/ml/hr
Normal 2.5 0.6 2.1 0.5 2.5 0.6
ESRD 2.6 1.1 1.4 0.4 1.8 0.7
P NS NS NS
Aldosterone ngldl
Normal 3.1 0.6 1.9 0.2 4.0 0.7
ESRD 8.5 2.4 7.4 2.2 10.6 3.2
P NS 0.04 NS
Norepinephrine pg/mi
Normal 286 64 188 22 216 24
ESRD 316 52 360 106 292 36
P NS NS NS
Epinephrine pg/mi
Normal 35 4 30 3 31 5
ESRD 44±8 39±6 39±5
P NS NS NS
a Numberof ESRD subjects was 8 at 8 and 16 hours, and 7 at 26 hours
of fasting.
17.7 2.1 mEq in control subjects and < 1 mEq in the ESRD
subjects, who were essentially anuric. Although plasma aldo-
sterone levels tended to be higher in ESRD patients, the two
groups were no different with respect to serum glucose and CO2
content, or plasma levels of insulin, renin activity, epinephrine,
or norepinephrine, after 8, 16 and 26 hours of fasting.
The response to epinephrine infusion is shown in Table 3.
Plasma levels of epinephrine increased in like fashion in both
groups during epinephrine infusion (P 0.28). The serum
potassium concentration in control subjects progressively de-
clined from 4.3 0.2 mEq/liter to 3.9 0.1 mEq/liter. In
contrast, the serum potassium concentration in ESRD patients
was 5.1 mEq/liter before and 5.0 0.4 mEq/liter after
infusion of epinephrine; the change in serum potassium in
ESRD patients during epinephrine infusion differed significantly
from that of controls (P = 0.005). In three ESRD patients, the
maximum observed potassium concentration exceeded 5.7
mEq/liter and occurred during the infusion of epinephrine.
Control subjects excreted 2.3 0.5 mEq of potassium in the
urine, while ESRD patients had no measurable urinary potas-
sium loss (no urine output), during epinephrine infusion.
The serum glucose level rose similarly, whereas plasma
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Table 3. Biochemical changes during epinephrine infusion (0.015 pg/kg body wt/min)
Minutes of epinephrine infusion
0 15 30 45 60
Potassium mEq/liter
Normala 4.3 0.2 4.1 0.1 4.1 0.1 4.0 0.1 3.9 0.1
ESRDb 5.1 0.3 5.2 0.5 5.1 0.4
P = 0.005
5.1 0.4 5.0 0.4
CO2 content mEqiliter
Normal 23.7 0.4 23.3 0.7 22.3 0.7 23.1 0.5 23.1 0.9
ESRD 23.1 1.1 22.9 1.0 22.1 1.2
P = 0.01
22.6 1.0 21.7 1.0
Glucose mg/dl
Normal 82 3 89 4 97 4 101 5 104 6
ESRD 76±6 82±7 87±8
P = 0.21
91±9 92±9
Insulin ,sU/mi
Normal 6.3 2.5 4.0 0.3 4.5 0.3 5.1 0.5 5.4 0.8
ESRD 4.7 1.1 5.0 1.1 5.5 1.4
P = 0.74
6.2 2.0 6.4 2.1
Renin activity ng/mi/min
Normal 2.5 0.6 4.1 1.6 3.9 1.6 4.4 1.8 3.2 1.3
ESRD 2.0 0.8 2.2 0.9 2.4 0.9
P = 0.68
2.4 1.1 2.4 1.1
Aldosterone ng/di
Normal 4.0 0.7 3.3 0.4 3.2 0.3 2.6 0.3 2.4 0.3
ESRD 11.3 3.6 11.6 3.5 11.7 3.4
P = 0.04
11.4 3.0 10.7 3.1
Norepinephrine pg/mi
Normal 216 24 266 33 230 22 233 19 253 31
ESRD 298 41 423 92 432 85
P = 0.37
453 76 410 77
Epinephrine pg/mi
Normal 31 5 184 20 220 32 214 34 191 28
ESRD 41 5 159 20 226 32
P = 0.28
176 32 162 31
/3-Hydroxybutyrate
mmoi/liter
Normal 378 102 — 669 223 — 576 140
ESRD 196 38 — 317 51
P = NS
— 454 64
Lactate mmol/iiter
Normal 1.48 0.15 — 1.89 0.23 — 2.15 0.23
ESRD 1.35 0.17 — 1.5 0.21
P = NS
— 2.0 0.24
a Number of normal control subjects = 9.
b Number of ESRD patients = 7.
insulin levels remained suppressed [91, in both control
(amended insulin/glucose ratio 13) and ESRD subjects
(amended insulin/glucose ratio  10) during epinephrine infu-
sion. Serum CO2 content declined in ESRD patients, but not in
controls (P 0.01). There was no difference between ESRD
and control subjects with respect to /3-hydroxybutyrate and
lactate levels, and neither was significantly related to the fall in
CO2 content observed in ESRD patients. Aldosterone levels
were significantly higher in ESRD patients, and did not change,
while the aldosterone concentration fell after epinephrine infu-
sion in control subjects (P = 0.04). Plasma renin activity was
not different during epinephrine infusion; while the plasma
norepinephrine levels increased to a greater extent in the ESRD
patients than in controls, the difference was not significant (P =
0.37).
Discussion
Although fasting hyperkalemia due to insulinopenia is a
known complication of diabetes mellitus, it is not widely
recognized that patients with ESRD on chronic hemodialysis
may develop hyperkalemia after fasting for 16 to 26 hours [1].
The present data confirm our earlier observation, and further
establish that chronic dialysis patients, in contrast to normal
control subjects, may not lower their serum potassium levels in
response to intravenous infusion of epinephrine. The serum
potassium concentration is dependent on external potassium
balance and the internal distribution of potassium between the
intracellular and extracellular compartments. Since external
potassium balance is regulated primarily by renal potassium
excretion, it is not surprising that hyperkalemia often occurs in
patients with ESRD, and is usually attributed to potassium
intake in excess of renal potassium excretion. Although the
effect of acidemia on internal potassium balance long has been
appreciated, it is increasingly apparent that other factors, such
as insulin [10] and f32-adrenoreceptor stimulation [11], may be
of greater importance to the acute regulation of internal potas-
sium balance.
Acidemia was not related to fasting hyperkalemia in our
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studies since the CO2 content did not differ between normal
subjects and ESRD patients prior to epinephrine infusion.
Similarly, fasting hyperkalemia could not be attributed to
aldosterone deficiency, as ESRD patients had higher plasma
aldosterone concentrations throughout the study than did the
control subjects. We previously suggested that the chief cause
of fasting hyperkalemia in ESRD patients was suppression of
plasma insulin levels, causing internal transfer of potassium
from cells to the extracellular fluid, in the setting of impaired
renal potassium excretion [1]. Hyperkalemia developed in
ESRD patients during a period of no potassium intake, and
therefore clearly was not the result of intake in excess of
excretion. Rather, the increase in serum potassium must have
resulted from redistribution of potassium from the intracellular
space. Similar potassium redistribution presumably occurred
during fasting in control subjects, yet hyperkalemia did not
ensue. Control subjects excreted 17.7 2.1 mEq of potassium
during the 26 hour fast prior to epinephrine infusion, in contrast
to < 1.0 mEq excreted by ESRD patients. Retention of 17 mEq
of potassium by the ESRD patients would be more than enough
to account for the observed rise in serum potassium. Since
plasma insulin levels clearly were suppressed, as expected
during fasting [9], and since the rise in serum potassium was not
related to either differences in serum bicarbonate levels or
potassium intake, the present data are consistent with our
previous hypothesis. Namely, hyperkalemia may develop dur-
ing fasting in ESRD patients as the result of insulinopenia,
causing transfer of potassium out of cells, coupled with the
inability of the ESRD patient to excrete this internal potassium
load. The role of insulinopenia is further supported by the
observation that significant hyperkalemia (serum potassium 
5.7 mEq/liter) in three patients was corrected by food intake.
Our data do not exclude the possibility that differences in
catecholamine concentrations may have contributed to fasting
hyperkalemia in our ESRD patients.
The present data suggest that ESRD patients may not exhibit
the same decrease in serum potassium concentration, in re-
sponse to epinephrine infUsion, as do normal control subjects.
Few other data describe the control of internal potassium
balance in patients with ESRD on chronic hemodialysis [12—15].
Two earlier studies examined the response of chronic hemodi-
alysis patients to epinephrine infusion [13, 14]. Although one
[14] of these studies concluded that /3-adrenergic-mediated
potassium disposal was intact in ESRD patients, the response
to epinephrine was heterogeneous in both; 13 of the 22 patients
responded with a significant drop in serum potassium, and 9
patients did not respond [13, 14]. The greater heterogeneity of
the serum potassium response in these patients, as compared to
our patients, most likely relates to differing study conditions.
Their patients either were not fasting or were basal (overnight
fast) when studied, and had higher serum insulin levels than did
our patients, who were studied after 26 hours of fasting. More
importantly, the amoulit of epinephrine infused (0.1 g/kg/min)
was considerably larger than that used in our study. We
deliberately chose a rate of epinephrine infusion which would
produce physiological (but lower than "stress") plasma levels
of epinephrine. Admittedly, it is possible that infusion of larger
amounts of epinephrine might have produced a greater potas-
sium-lowering effect in our patients. Nevertheless, the plasma
epinephrine concentration increased similarly in both groups,
and serum potassium concentration decreased in normal sub-
jects, but not in ESRD patients (P = 0.005), after epinephrine
infusion. Similar results have been observed in basal dialysis
patients, after inhalation of albuterol [15].
The disparate change in potassium after epinephrine was
unrelated to differences in insulin and glucose concentrations,
since serum glucose increased similarly and plasma insulin
remained suppressed in ESRD and control subjects. Hepatic
glucose production may be increased by epinephrine, as the
result of suppression of insulin release, stimulation of glucagon
release, or direct stimulation of gluconeogenesis. In our pa-
tients, both glucagon-mediated glycogenolysis and an effect on
insulin seem unlikely since hepatic glycogen stores should have
been depleted after 26 hours of fasting prior to epinephrine
infusion [16], and insulin levels did not change while glucose
levels increased. Thus, an epinephrine-mediated increase in
gluconeogenesis seems more likely [17]. It is generally agreed
that epinephrine increases glucagon and insulin secretion via
/3-receptor stimulation, while concomitant a-adrenergic effects
on islet cells usually serve to suppress insulin secretion. Al-
though stimulation of gluconeogenesis appears to involve /3-
and/or a-adrenergic stimulation in different species, some data
indicate that the effect is /3-mediated in humans [181. These and
other [13—15] data suggest that some /3-mediated effects of
epinephrine are comparable in normal subjects and patients
with ESRD, but that ESRD patients may behave differently
than do normal subjects with respect to potassium. While this
might be due to differing sensitivities [15] of f32-adrenore-
ceptors, particularly those on hepatic and skeletal muscle cells
[19, 20], or increased receptor occupancy by endogenous
epinephrine (13), other explanations are possible. The present
data neither prove the presence of abnormal /32-receptor sensi-
tivity nor exclude a post-receptor defect. Increased receptor
occupancy by endogenous epinephrine, however, seems un-
likely since epinephrine levels were comparable before, after
and during infusion in our subjects. Unlike norepinephrine,
epinephrine levels are not elevated in chronic dialysis patients;
in fact, normal [21, 22] and subnormal [23] concentrations have
been described. Additionally, the normal levels of epinephrine
seen in our patients may, in part, reflect their fasting state, as
fasting suppresses epinephrine release. Since norepinephrine
levels may be higher in ESRD patients than in normal subjects
[22, 24], it is possible that greater a-adrenergic stimulation in
ESRD patients may counterbalance the potassium-lowering
action of f32-agonists [25]. In this regard, norepinephrine levels
tended to be higher in our ESRD patients during epinephrine
infusion than in controls; however, the difference between the
groups failed to achieve statistical significance (P = 0.37).
Similarly, the relatively higher levels of norepinephrine ob-
served in our ESRD patients, coupled with normal concentra-
tions of epinephrine, might have contributed to the observed
rise in potassium in these patients during fasting. Finally, the
slight but definite fall in serum CO2 content in ESRD patients
during epinephrine infusion may have blunted further the
potassium response to epinephrine. The reason for the decline
in serum CO2 content is unclear, given the similar changes in
lactate and /3-hydroxybutyrate in the two groups.
In contrast to the above evidence suggesting diminished
lowering of potassium by epinephrine in ESRD patients, several
studies have demonstrated that /3-adrenergic blockade may
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impair extrarenal potassium disposal in normal subjects 126,
27], or produce hyperkalemia in patients with ESRD [14, 28].
Nonetheless, there is little convincing evidence that catechol-
amine secretion is increased in response to increases in serum
potassium [11, 29]. DeFronzo, Bia and Birkhead postulated that
increased blood potassium concentrations might activate sym-
pathetic nerves innervating hepatic and skeletal muscle cells,
with resultant local uptake and degradation of epinephrine but
no increase in plasma levels, and/or that basal levels of epineph-
rine and sympathetic nervous system activity are necessary for
normal internal potassium disposal [11]. If this is so, differing
basal levels, or differing responses to such basal levels, of
catecholamines may predispose ESRD patients to development
of hyperkalemia under appropriate conditions (that is, fasting
with suppression of plasma insulin levels). Since long-term
fl-blockade regularly causes the serum potassium concentration
to increase in chronic dialysis patients [14, 281, it is possible that
catecholamines are relatively more important to the control of
internal potassium balance during nonfasting conditions (that is,
normal insulin levels and exogenous potassium loading).
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